MedTrace Logo

Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan

NCT01716260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2016-05-27

No results posted yet for this study

Summary

This research is intended to study the efficacy of chloroquine (CQ) and primaquine (PQ) for Plasmodium vivax (P.vivax) infection, and also to study the recurrence rate among patients with P.vivax malaria on standard doses of CQ and PQ. For this study, PQ will be withheld for 28 days so as to study the efficacy of CQ alone.

This study will assess whether CQ is still effective against P.vivax or whether there are resistant P.vivax strains in Bhutan.

Conditions

  • Vivax Malaria

Interventions

DRUG

Chloroquine

DRUG

Primaquine

Sponsors & Collaborators

  • Ministry of Health, Bhutan

    collaborator OTHER_GOV

  • Menzies School of Health Research

    lead OTHER

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Bhutan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716260 on ClinicalTrials.gov